stoxline Quote Chart Rank Option Currency Glossary
  
XOMA Corporation (XOMA)
16.04  -0.16 (-0.99%)    12-07 16:00
Open: 15.8365
High: 16.47
Volume: 17,221
  
Pre. Close: 16.2
Low: 15.8365
Market Cap: 184(M)
Technical analysis
2023-12-07 4:24:22 PM
Short term     
Mid term     
Targets 6-month :  20.24 1-year :  22.46
Resists First :  17.33 Second :  19.22
Pivot price 15.51
Supports First :  14.27 Second :  11.87
MAs MA(5) :  16.04 MA(20) :  15.58
MA(100) :  15.83 MA(250) :  18.02
MACD MACD :  -0.2 Signal :  -0.3
%K %D K(14,3) :  69.1 D(3) :  67.9
RSI RSI(14): 51.2
52-week High :  23.51 Low :  13.47
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ XOMA ] has closed below upper band by 25.8%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.51 - 16.6 16.6 - 16.68
Low: 15.6 - 15.73 15.73 - 15.83
Close: 15.87 - 16.06 16.06 - 16.2
Company Description

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Headline News

Tue, 05 Dec 2023
XOMA (NASDAQ:XOMA) three-year losses have grown faster than shareholder returns have fallen, but the stock soars 10% this past week - Simply Wall St

Tue, 07 Nov 2023
Xoma: Q3 Earnings Snapshot - San Francisco Chronicle

Tue, 07 Nov 2023
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ... - Yahoo Finance

Tue, 31 Oct 2023
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive ... - Yahoo Finance

Tue, 31 Oct 2023
XOMA gets $5M milestone upon FDA's acceptance of Day One's Tovorafenib NDA - Seeking Alpha

Mon, 28 Aug 2023
Novartis Abandons Xoma-Partnered Antibody for Pancreatic Cancer - BioSpace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 11 (M)
Shares Float 8 (M)
Held by Insiders 0.6 (%)
Held by Institutions 65.3 (%)
Shares Short 312 (K)
Shares Short P.Month 480 (K)
Stock Financials
EPS -2.81
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.22
Profit Margin 0 %
Operating Margin -697.3 %
Return on Assets (ttm) -10.4 %
Return on Equity (ttm) -22.7 %
Qtrly Rev. Growth 84 %
Gross Profit (p.s.) 0.51
Sales Per Share 0.38
EBITDA (p.s.) -1.89
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow 3 (M)
Stock Valuations
PE Ratio -5.71
PEG Ratio -0.4
Price to Book value 1.73
Price to Sales 41.79
Price to Cash Flow -10.18
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android